The analysis of positron tomographic studies of 3,4-dihydroxyphenylethylamine (dopamine) metabo lism in which e8F]6-fluoro-L-3,4-dihydroxyphenylalanine (F-dopa) is used as a tracer is confounded by the presence of [18Fj6-fluoro-3-0-methyl-L-3,4-dihydroxyphenylala nine (OMFD). This labeled molecule, formed by the ac tion of peripheral cathechol-O-methyltransferase on F-dopa, crosses the blood-brain barrier and contributes to the radioactivity measured by the tomograph. Correc tions for this radioactivity in the brain have been pro posed. They rely upon the assumption that regional vari ations in the handling of this molecule by the brain are negligible. Although this assumption is pivotal for the proper quantification of dopamine metabolism using F-dopa, the distribution and kinetics of OMFD have never been studied in humans. We present results in hu mans that show that there is little selective regional 18F accumulation in the brain, that the distribution volume of Positron tomography used with a labeled precur sor of 3,4-dihydroxyphenylethylamine (dopamine) offers the best approach to the investigation of pre synaptic dopamine metabolism in living humans. The most commonly used tracer is an analogue of L-3,4-dihydroxyphenylalanine (L-dopa) labeled with fluorine-I 8: [ l sF16-fluoro-L-dopa (F -dopa). How ever, the analysis of the data has been confounded by the presence of other labeled species formed in the body, which cross the blood-brain barrier. Like L-dopa, F-dopa acts as a substrate for catechol-O-
OMFD is close to unity, and that a single, reversible com partment is adequate to model the measured time course of radioactivity after an OMFD injection. Analysis of plasma samples for labeled metabolites showed that more than 95% of the radioactivity was associated with OMFD at all times. Our results for OMFD kinetics are in accord with published results obtained in nonhuman primates and for the bidirectional transport of large neutral amino acids across the blood-brain barrier measured using a synthetic amino acid. However, our results also indicate that there are small but significant differences in OMFD kinetics in different parts of the brain that may prevent inferences about the handling of OMFD in one part of the brain from being extended to other parts of the brain. Key Words: Compartmental analysis-Dopamine metabo lism-6-Fluoro-3-0-methyl-L-dopa-6-Fluoro-L-dopa Graphical analysis-Positron tomography-Striatum. methyltransferase (COMT), forming eSF16-fluoro-3-0-methyl-L-dopa (OMFD). OMFD, formed in the peripheral organs and the red blood cells, is able to cross the blood-brain barrier and contributes to the radioactivity measured by the tomograph. Correc tions for this radioactivity in dopaminergic regions of the brain have been proposed (Martin et aI. , 1989; Huang et aI. , 1991; Gjedde et aI. , 1991; Chan et aI., 1992) . These corrections usually rely upon one or more of the following assumptions: that the distribution of OMFD is homogeneous throughout the gray matter; that a single, reversible compart ment is adequate to model the time course of radio activity due to OMFD in the brain; and that the distribution volume of OMFD in all regions of the brain is close to unity. It is sometimes further as sumed that the time course of radioactivity associ ated with OMFD is similar in dopaminergic and nondopaminergic regions of the brain. The first three of these assumptions have been examined by Doudet et aI. (1991) in normal rhesus monkeys and in animals with I-methyl-4-phenyl-l ,2,3 ,6-tetra hydropyridine-induced lesions in the nigrostriatal system. The purpose of the present study was to examine the regional distribution of OMFD, and its kinetics in the human brain. These studies have never been described in humans, although this in formation is crucial for the proper quantification of dopamine metabolism using F-dopa.
METHODS

Preparation of the tracers
Anhydrous hydrogen fluoride (HF; electronic grade; Air Products), boron trifluoride (Matheson), HPLC-grade tetrahydrofuran, 3-0-methyl-dopa, and L-dopa (Aldrich) were used without further purification. Fluorine-18labeled F2 was produced from the 180(p, n)lSF reaction using a Siemens II-Me V negative ion proton cyclotron.
Synthesis of OMFD
A mixture of [lsFlF2 (50 ,... ., mol) in neon (0.03% F2 in neon) was bubbled through a solution of 3-0-methyl-dopa (70 ,... ., mol) in anhydrous HF containing boron trifluoride at -70°C. Fluorine-18-labeled OMFD was isolated from the reaction mixture using reverse-phase HPLC (Whatman M9 Partisil 10/50 ODS-2 column with 0.15% trifluoroace tic acid in water containing 4.5% tetrahydrofuran as the mobile phase at 3.5 mllmin). The 6-fluoro isomer was further purified (radiochemical purity 97 ± 1%) from traces of 3-0-methyl-dopa and [18Fl2-fluoro-3-0-methyl dopa using a CI 8 semipreparative reverse-phase column (0.78 x 30 cm; Vydac) and 0.1% acetic acid as the mobile phase at 3.5 mllmin. The final product was characterized using high-resolution mass spectrometry and IH, \3C, and 19F nuclear magnetic resonance (NMR). Following isola tion of the final product, it was evaporated to dryness, reconstituted in physiologic saline, and sterilized by fil tration through a 0.2-,... ., m Millipore filter.
Synthesis of F-dopa
A mixture of [18FlF2 (50 , ... ., mol) in neon (0.03% F2 in neon) was bubbled through a solution of L-dopa (85 ,... ., mol) in anhydrous HF containing boron trifluoride at -70°C. Fluorine-18-labeled 6-fluorodopa was isolated from the reaction mixture using reverse-phase HPLC (Whatman M9 Partisil 10/50 ODS-2 column with 0.15% trifluoroacetic acid in water containing 4.5% tetrahydro furan as the mobile phase at 2.5 ml/min). The 6-fluoro isomer was further purified (radiochemical purity, 97 ± 1%) from traces of L-dopa and [,sFl2-fluorodopa using a CI 8 semipreparative reverse-phase column (0.78 x 30 cm; Vydac) and 0.1% acetic acid as the mobile phase at 1.5 mllmin. The final product was characterized using high resolution mass spectrometry and 'H, I 3C, and 19F NMR. Following isolation of the final product, it was evaporated to dryness, reconstituted in physiologic saline, and ster ilized by filtration through a 0.2-,... ., m Millipore filter.
Scanning procedure
Four normal male volunteers, aged 46,20,21, and 28, wert1 studied by positron tomography after informed con sent had been obtained. Each subject was studied twice during 1 week: once after injection of between 5 and 10 mCi of OMFD (sp act, 2 Ci/mmol) and once after injection of between 5 and 10 mCi of F-dopa (sp act, 2 Ci/mmol). The studies were repeated in subject 1 after a 6-month interval. All subjects were studied after an overnight fast. On no occasion were the subjects pretreated with carbi dopa.
Each subject was positioned in the scanner, with his head immobilized by a headholder in a position that al lowed the brain, from the vertex to the cerebellum, to be covered by the axial field of view of the tomograph. Sub jects were asked not to move during the study and were not spoken to for the duration of the examination. Low ambient lights and background noise defined the environ ment. Subjects' heads were positioned with respect to the orbitomeatal line, and the positioning was reproducible within a few millimeters on the two occasions.
The tomograph used was an ECAT 953/31 (Siemens/ CTI) that allows the simultaneous examination of 31 over lapping slices. The axial field of view is 10.8 cm; the spatial resolution is 6 mm (full width at half-maximum) in the three spatial dimensions. Images were reconstructed using a Hann filter with a cutoff frequency of 0.5. A 30min transmission scan, using a 68Ge ring source, was ob tained before each study to correct for attenuation.
After a bolus injection of either F-dopa or OMFD, sub jects were scanned for 12 frames at 10 s/frame, 6 frames at 30 s/frame, and 23 frames at 300 s/frame, for a total of 2 h. In one subject, both studies were extended to 4 h. Arterialized venous blood samples (5 to 10 ml) were taken throughout each study according to the following proto col: every 10 s for the first 2 min; at 3, 4, 5, 7.5,10,12.5, and 15 min; at 20, 25, 30,40, 50, and 60 min; at 75, 90, 105 , and 120 min; and every 30 min thereafter. These blood samples were kept in ice before being centrifuged in a refrigerated centrifuge. Radioactivity in the plasma was counted in a well-counter, which had been calibrated to the tomograph. All samples were decay-corrected to the time of injection. These counts were corrected for in jected dose and are expressed as a percentage of the in jected counts per minute. The samples at 30, 60, and 120 min were also assayed for the tracer and other labeled metabolites. Plasma amino acids were quantitated in blood samples obtained before the start of each experi ment.
Regions of interest were defined around the left stria tum and the right striatum and in the frontal lobe, the occipital lobe, and the cerebellum using the F-dopa study as a guide. The area of each region was, on average, 5.5, 5.5,5.0, 16, and 15 cm 2 , respectively. The time course of radioactivity, expressed as counts per second per pixel, was calculated for each region. These counts were also corrected for dose injected and, using the calibration fac tor between the well-counter and the tomograph, are ex pressed in the same units as the plasma counts (fraction of cpm injected/m!). This was done so that tissue and blood data could be expressed in the same units, and compari sons of the time course of radioactivity made between subjects (as in Fig. 2 ).
Metabolite analysis
Fluorine-18-labeled metabolites of F-dopa and OMFD in plasma were analyzed according to the method of McLellan et al. (1991) . Before and after each run, authen tic F-dopa and OMFD were mixed with plasma and run through the separation system. Recovery of these stan dards was better than 96%.
Data analysis
Using the time course of radioactivity in the plasma as an input function, a compartmental analysis procedure was implemented. The differential equations for the model were integrated numerically using fourth-and fifth order Runge-Kutta-Fehlberg methods (The MathWorks, Inc., 1990; Press et aI., 1986) . The impulse response of the model was then convolved with the plasma time activity curve. Weighted least-squares optimization of the rate constants was performed using an implementation of the Neider-Meade simplex algorithm (The MathWorks, Inc., 1990; Press et aI., 1986) ; each of the values used to define the time course of radioactivity was weighted by the reciprocals of the total coincidence counts acquired in the region of interest in the time frame that corresponded to that point. Progressively more complex models were solved and evaluated by an F test. In this procedure, the weighted residual sum of squares between the calculated and the measured outputs is evaluated for progressively more complex models, and the best model chosen by means of an F test. The lower-order model is sequentially rejected until a model is found for which the probability of getting a value for the F statistic larger than that just calculated is no longer significant (Landaw and DiSteph ano, 1984) .
RESULTS
OMFD crossed the blood-brain barrier and accu mulated specifically in gray matter and cerebellum. There was little variation in localized preferential accumulation of OMFD in the human brain, al though the highest accumulation was observed in the striatum in each of the five studies; total counts per pixel in the striatal regions of interest averaged 10% higher than in the cortical regions (Fig. I) .
Differences in the measured time-activity curves for the striatum, the frontal lobe, the occipital lobe, (A) <..:> and the cerebellum were noted; from 50 mit;! on ward, the striatal time-activity curve was higher than that from other regions (Fig. 2) .
A single reversible compartment was adequate to model the measured time course of radioactivity in striatum, frontal and occipital lobes, and cerebel lum after an OMFD injection. The fitting with more complicated models was found, by F test, not to be significantly better than this simple model [the F value with (2,57) degrees of freedom was smaller than the threshold value of 8.49 for p < 0.05]. The values for the optimized parameters are given in Table 1 . Using the paired t test, the rate of influx (KIO) of OMFD was significantly lower in striatum compared to cerebellum (0.025 > P > 0.010) and in frontal cortex compared to cerebellum (0.025 > P > 0.010). The rate of efflux (ko]) was also significantly lower in striatum compared to cerebellum (0.010 > p > 0.005) and in frontal cortex compared to cere bellum (0.025 > P > 0.010). In occipital cortex the influx constant was not different from that mea sured in cerebellum, whereas the efflux constant was different (0.050 > P > 0.025). The distribution volume (Ve) of OMFD was roughly equal to 1; the average value for striatum was 1.04, and the aver age value for cortex and cerebellum was 0.92 (Table  I) . Plasma amino acid concentrations were within the normal range in all cases.
Analysis of plasma samples obtained 30, 60, and 120 min after injection of OMFD revealed that 95 ± 3% of the radioactivity in the plasma was associated with OMFD. This fraction did not show any tem poral trend. The identity of the compound(s) with which the remainder of the radioactivity was asso ciated was not confirmed, but it appeared in the anionic fraction that contains either acids or sul fated conjugates.
DISCUSSION
This study of the distribution and kinetics of OMFD in the human brain allows us to examine the assumptions that are made when corrections for OMFD are introduced in the quantification of do pamine metabolism using F-dopa as a tracer. The 
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first assumption is that the distribution of OMFD is homogeneous throughout the gray matter. Follow ing the injection of OMFD, we observed an accu mulation of the tracer in the gray matter and cere bellum. However, there was a preferential accumu lation in the striatum of about 10% compared to the cortex. This was supported by inspection of the time-activity curves obtained from regions of inter est placed over the striatum, the frontal and occip ital lobes, and the cerebellum, which showed that the time course of radioactivity was not the same in these areas. These results are consistent with the findings of Doudet et al. (1991) in the rhesus mon key brain. They reported that "paired comparisons between regions did demonstrate some significant differences between regional values (e.g. between basal ganglia and occipitoparietal cortex) although the magnitude of these differences was not large." Depending on the precision of the quantitative method and the magnitude of the OMFD contribu tion in a given F-dopa protocol, these small but sig nificant regional differences may or may not inval idate the assumption of homogeneity. The second assumption is that the distribution volume for OMFD in all regions of the brain is close to unity. The distribution volumes that we calcu lated for different brain regions are close to unity; however, the calculated volume for nonstriatal re gions was less than unity, whereas the calculated volume for the striatum was generally higher than 1, indicating some preferential retention of the label in this structure. This finding is consistent with results previously obtained in other species (Doudet et aI., J Cereb Blood Flow Metab, Vol. 14, No.4, 1994 1991). A possible explanation for this finding is , that small quantities of OMFD are demethylated to F-dopa in the striatum (Revera-Calimlin, 1974) .
The third assumption is that the simplest model that describes the kinetics of OMFD in brain re gions is a one-compartment, two-parameter model. Despite differences observed in the time-activity curves obtained in different brain regions, a single reversible compartment was adequate to describe the kinetics of OMFD in striatum, frontal and oc cipital cortex, and cerebellum. More complicated models did not statistically improve the fit, even in the striatum, where we observed some evidence of preferential retention. The input function corre sponds to the presence of the radiolabel in the plasma; results of the biochemical assay of plasma samples show that 95% of the radioactivity present in plasma for the duration of the experiment was OMFD. This function, then, feeds a single compart ment that must represent radioactivity in brain tis sue, The two rate constants must then reflect the bidirectional transport of the label across the blood brain barrier.
Because OMFD is transported across the blood brain barrier by the same large neutral amino acid carrier as other naturally occurring amino acids, and because it is not metabolized to any large extent and is not likely to be incorporated into proteins, its transport kinetics should be similar to those re ported for the synthetic amino acid ["C]aminocyc lohexanecarboxylate by Koeppe et al. (1990) . The values that we report for K l O, kO l ' and the distribu tion volume are similar to those reported by those authors (Koeppe et aI. , 1990) . Our values are also comparable to those calculated by Doudet et al. (1991) for OMFD in the monkey. It is interesting to note that Doudet et al. also reported small, but con sistent differences among parameter estimates for striatum, cortex, and cerebellum (Table 2) .
Our results have important implications in the modeling of dopamine metabolism using F-dopa. In general, the methods reported in the literature can be categorized broadly as graphical analyses or compartmental analyses. In graphical analyses, the measured variables are transformed and plotted so that the numerical parameters of the system can be estimated through a regression analysis of this graph (Patlak et aI., 1983; Patlak and Blasberg, 1985) . The result is usually an "influx constant," which is a measure of the flow of material through the system and into an irreversible compartment at steady state. Various means of correcting for OMFD have been applied in conjunction with this method. For example, Martin et al. subtracted cor tical radioactivity from total striatal radioactivity at (Doudet et al., 1991) and a synthetic amino acid in humans (Koeppe et al., 1990) each time point to obtain "specific striatal activity" (Martin et al., 1989) , and corrected the time course of radioactivity for OMFD contribution to obtain the time course of F-dopa in plasma (Martin et al., 1989; Chan et al., 1992) before using these corrected values in the graphical analysis of Patlak. Our study demonstrates that the time course of radioactivity attributable to OMFD in striatal regions is different from that observed in other regions. If the cerebel lar or cortical time-activity curve were subtracted from that in the striatum, the effect would be to undercorrect the latter section of the specific stri atal curve.
In compartmental analyses, a model is proposed and the set of differential equations describing the transport and metabolism of the tracer is integrated to estimate the numerical parameters of the system. Compartmental models that explicitly account for the contribution of OMFD have been proposed by Kuwabara et al. (1993) and Huang et al. (1991) . Both groups use a single, reversible compartment to model the kinetics of OMFD in the brain, a premise supported by our results. They assume that the dis tribution volume of OMFD in the brain is equal to 1, or that its variability among brain regions is negli gible, and solve for values for the transport of OMFD across the blood-brain barrier. Huang et al. (1991) could not determine uniquely the forward transport rate of OMFD from blood to brain from a single striatal curve. They fixed this rate constant to be 1.7 times greater than that of F-dopa. Their rate constant for F -dopa was 0. 0313 ml min -I g -I , which would make their rate constant for OMFD equal to 0.0532, on average. Kuwabara et al. (1993) fixed the forward transport rate of OMFD to be 2. 3 times greater than that of F-dopa. This proportion was based on data that they had obtained from rats (Reith et al., 1990) . Their rate constant for F -dopa was 0. 033 ml min -I g-I , which would make their rate constant for OMFD equal to 0.0759. Our anal ysis provides independent measures for this distri bution volume and these rate constants, and for the variability of these values between individuals.
In summary, this investigation reveals that infer ences about the handling of OMFD in one part of the brain may not be applicable to other parts of the brain. We provide independently determined values for the bidirectional transport of OMFD and for the regional variations in the distribution volume for OMFD in the brain. We have examined the assump tions that have been used to correct for OMFD when studying dopamine metabolism with F-dopa in positron tomography. Our results offer estimates of the degree to which these assumptions hold and should provide a basis for the reevaluation of the F-dopa model.
